| David K Kuechle, MD | |
|
7320 216th St Sw, Suite 320, Edmonds, WA 98026-8006 | |
| (425) 673-3900 | |
| (425) 673-3910 |
| Full Name | David K Kuechle |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 35 Years |
| Location | 7320 216th St Sw, Edmonds, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508865429 | NPI | - | NPPES |
| 200033896 | Other | WA | RAILROAD MEDICARE |
| 0118246 | Other | WA | STATE L/I |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD00032709 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Swedish Edmonds Hospital | Edmonds, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Proliance Surgeons Inc Ps | 8527972900 | 388 |
News Archive
The Washington Post reports on a new study, which finds Food and Drug Administration warnings did not cause a sharp drop in the use of these drugs.
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center, with colleagues in Spain and Germany, have unraveled how elevated levels of particular proteins in cancer cells trigger hyperactivity in other proteins, fueling the growth and spread of a variety of cancers.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
Isobionics has finalized the development of a breakthrough fermentation process for production of its natural Valencene Pure. This product, which is an aroma substance for the food, beverage, flavor and fragrance industry, is now available on a commercial scale. Compared with conventional valencene, which is produced from oranges, it offers the advantage of high purity and constant quality.
› Verified 2 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
The Washington Post reports on a new study, which finds Food and Drug Administration warnings did not cause a sharp drop in the use of these drugs.
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center, with colleagues in Spain and Germany, have unraveled how elevated levels of particular proteins in cancer cells trigger hyperactivity in other proteins, fueling the growth and spread of a variety of cancers.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
Isobionics has finalized the development of a breakthrough fermentation process for production of its natural Valencene Pure. This product, which is an aroma substance for the food, beverage, flavor and fragrance industry, is now available on a commercial scale. Compared with conventional valencene, which is produced from oranges, it offers the advantage of high purity and constant quality.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David K Kuechle, MD 805 Madison St, Suite 901, Seattle, WA 98104-1172 Ph: (206) 264-8100 | David K Kuechle, MD 7320 216th St Sw, Suite 320, Edmonds, WA 98026-8006 Ph: (425) 673-3900 |
News Archive
The Washington Post reports on a new study, which finds Food and Drug Administration warnings did not cause a sharp drop in the use of these drugs.
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center, with colleagues in Spain and Germany, have unraveled how elevated levels of particular proteins in cancer cells trigger hyperactivity in other proteins, fueling the growth and spread of a variety of cancers.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
Isobionics has finalized the development of a breakthrough fermentation process for production of its natural Valencene Pure. This product, which is an aroma substance for the food, beverage, flavor and fragrance industry, is now available on a commercial scale. Compared with conventional valencene, which is produced from oranges, it offers the advantage of high purity and constant quality.
› Verified 2 days ago
Dr. Darcy Silver Foral, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7320 216th St Sw, Suite 320, Edmonds, WA 98026 Phone: 206-673-3900 | |
Dr. Brian D. Cameron, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7320 216th St Sw, Suite 320, Edmonds, WA 98026 Phone: 425-673-3900 Fax: 425-673-3910 | |
Dr. Jeffrey P Remington, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 7320 216th St Sw, Suite 320, Edmonds, WA 98026 Phone: 425-673-3900 Fax: 425-673-3910 | |
Dr. James Robert Alberts, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 7320 216th St Sw, Suite 320, Edmonds, WA 98026 Phone: 425-673-3900 Fax: 425-673-3910 | |
Dr. Sean M Amann, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7320 216th St Sw Ste 320, Edmonds, WA 98026 Phone: 425-673-3900 Fax: 425-673-3910 | |
Michael Bor-hwa Lee, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7320 216th St Sw, Suite 320, Edmonds, WA 98026 Phone: 425-673-3900 Fax: 425-673-3910 |